LDLR and atherosclerosis: PCSK9 inhibitors are a relatively new type of lipid-lowering drug [11] that prolongs the life span of low density lipoprotein receptor (LDLR) and maintains cholesterol homeostasis in vivo, making them innovative pharmacological targets for the treatment of atherosclerosis [12].